Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab OLE in Generalized Myasthenia Gravis
NCT04650854Phase 3Completed
- Sponsor
- UCB
- Start
- Feb 2021
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of rozanolixizumab in myasthenia gravis (MG), sponsored by UCB. Started Feb 2021; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04650854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04650854.